A new trading day began on Friday, with Monopar Therapeutics Inc (NASDAQ: MNPR) stock price down -3.54% from the previous day of trading, before settling in for the closing price of $44.68. MNPR’s price has ranged from $1.65 to $54.30 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 57.77%. With a float of $3.95 million, this company’s outstanding shares have now reached $6.10 million.
In an organization with 10 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Monopar Therapeutics Inc (MNPR) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Monopar Therapeutics Inc is 35.33%, while institutional ownership is 45.53%. The most recent insider transaction that took place on Oct 28 ’24, was worth 25,188. In this transaction Chief Financial Officer of this company bought 1,550 shares at a rate of $16.25, taking the stock ownership to the 1,550 shares. Before that another transaction happened on Jun 20 ’24, when Company’s Chief Operating Officer bought 20,508 for $0.74, making the entire transaction worth $15,254. This insider now owns 186,132 shares in total.
Monopar Therapeutics Inc (MNPR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 57.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.48% during the next five years compared to -14.80% drop over the previous five years of trading.
Monopar Therapeutics Inc (NASDAQ: MNPR) Trading Performance Indicators
Here are Monopar Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.98, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -2.38 in one year’s time.
Technical Analysis of Monopar Therapeutics Inc (MNPR)
Let’s dig in a bit further. During the last 5-days, its volume was 67860.0. That was better than the volume of 67093.0 it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 45.39%. Additionally, its Average True Range was 5.07.
During the past 100 days, Monopar Therapeutics Inc’s (MNPR) raw stochastic average was set at 77.68%, which indicates a significant increase from 43.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 128.66% in the past 14 days, which was lower than the 350.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.85, while its 200-day Moving Average is $12.72. However, in the short run, Monopar Therapeutics Inc’s stock first resistance to watch stands at $44.56. Second resistance stands at $46.02. The third major resistance level sits at $48.44. If the price goes on to break the first support level at $40.68, it is likely to go to the next support level at $38.26. The third support level lies at $36.80 if the price breaches the second support level.
Monopar Therapeutics Inc (NASDAQ: MNPR) Key Stats
With a market capitalization of 262.91 million, the company has a total of 6,102K Shares Outstanding. Currently, annual sales are 0 K while annual income is -8,400 K. The company’s previous quarter sales were 0 K while its latest quarter income was -1,300 K.
